Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DONEPEZIL HYDROCHLORIDE
Helsinn Birex Therapeutics Ltd
10 Milligram
Film Coated Tablet
2009-09-11
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0915/020/002 Case No: 2045697 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to HELSINN BIREX THERAPEUTICS LTD DAMASTOWN, MULHUDDART, DUBLIN 15, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product DONELINN 10MG FILM-COATED TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 11/09/2009 until 10/09/2014. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 24/09/2009_ _CRN 2045697_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Donelinn 10mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg of donepezil hydrochloride respectively. Excipients include: Lactose 194.70mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated Tablet Pale yellow, round, biconvex film-coated tablets, 9 mm in diameter and marked DZ 10 on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Donelinn tablets are indicated for the symptomatic treatment of mild or moderate dementia in Alzheimer's disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults/elderly_ The initial dose is 5 mg Read the complete document